Core Viewpoint - The announcement indicates that the pharmaceutical company has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for its new drug, SYH2072, which is a potent aldosterone synthase inhibitor [1] Group 1: Product Details - SYH2072 is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively lowers plasma aldosterone levels without affecting cortisol levels [1] - The approved clinical indications for SYH2072 are uncontrolled hypertension and primary aldosteronism [1] - Preclinical studies have shown that SYH2072 selectively inhibits aldosterone synthase activity, significantly reducing plasma aldosterone levels in animal disease models and dose-dependently lowering blood pressure in hypertension models [1] Group 2: Drug Potential and Development - The product exhibits favorable pharmacokinetic (PK) characteristics and safety, positioning it as a potential best-in-class drug [1] - The company has submitted multiple patent applications for SYH2072 both domestically and internationally [1] - Given the broad clinical demand for aldosterone synthase inhibitors, SYH2072 holds significant clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary aldosteronism [1]
石药集团：强效醛固酮合成酶抑制剂(SYH2072片)在中国获临床试验批准